|TiGenix||Director of Strategy and Corporate Development||Spain|
How can we define a mutually beneficial collaboration between an academic institution and a resulting spin-off?
Dr. Miguel Mulet MEng DPhil MBA, holds a Masters degree in Electrical Engineering from Imperial College, London and a Doctorate in Bioengineering (Cardiovascular Imaging) from the University of Oxford where he also obtained an MBA from the Said Business School. In 2000 he co-founded Mirada Solutions, one of Oxford’s most successful spin-offs, now part of Siemens Molecular and Mirada Medical. He then joined Janssen Pharmaceutica’s EMEA organization where he was in charge of leading operational excellence efforts across the region. In 2007 Miguel joined Genetrix a private biotech incubator in Spain as Business Development Director to oversee the development of Coretherapix, a start-up developing a cardiovascular regenerative medicine cell product which was acquired by TiGenix in 2015, as well as several other projects in biotech and medtech. Since the Coretherapix acquisition, Miguel has taken the role of Director of Strategy and Corporate Development at TiGenix where he is in charge of devising and coordinating its innovation strategy which includes inlicensing and outlicensing activities and setting up research collaborations with academia and corporate partners in the broad space of regenerative medicine for inflammation, auto-immune and GI therapeutic areas.